Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:APM TSE:CUS NYSE:DNA TSE:VBV On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPMAptorum Group$1.97+1.5%$1.02$0.46▼$7.49$10.37M-0.171.42 million shs4.22 million shsCUSChemtrade Electrochem Inc,C$0.00C$1.18▼C$1.65C$306.50MN/A271,090 shs13,269 shsDNAGinkgo Bioworks$9.76+1.6%$8.90$5.00▼$16.85$561.91M1.481.43 million shs1.23 million shsVBVVBI VaccinesC$0.00C$3.85▼C$7.60C$308.86MN/A3,637 shs1,300 shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPMAptorum Group+1.55%+111.83%+80.75%+136.98%-48.70%CUSChemtrade Electrochem Inc,0.00%0.00%0.00%0.00%0.00%DNAGinkgo Bioworks+1.86%-9.43%+13.65%+24.53%-27.03%VBVVBI Vaccines0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAPMAptorum Group1.5061 of 5 stars0.05.00.00.02.41.70.6CUSChemtrade Electrochem Inc,N/AN/AN/AN/AN/AN/AN/AN/ADNAGinkgo Bioworks0.7913 of 5 stars1.01.00.00.02.32.51.3VBVVBI VaccinesN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAPMAptorum Group 0.00N/AN/AN/ACUSChemtrade Electrochem Inc, 0.00N/AN/AN/ADNAGinkgo Bioworks 2.00Hold$8.50-12.88% DownsideVBVVBI Vaccines 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAPMAptorum Group$430K24.51N/AN/A$2.20 per share0.90CUSChemtrade Electrochem Inc,N/AN/AN/AN/AN/AN/ADNAGinkgo Bioworks$227.04M2.52N/AN/A$13.17 per share0.74VBVVBI VaccinesC$3.36M0.00N/AN/AC$1.01 per share0.00Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAPMAptorum Group-$4.27MN/A0.00∞N/AN/AN/AN/A7/30/2025 (Estimated)CUSChemtrade Electrochem Inc,N/AN/A0.00N/AN/AN/AN/AN/AN/ADNAGinkgo Bioworks-$547.03M-$9.16N/AN/AN/A-198.84%-52.35%-27.14%8/14/2025 (Estimated)VBVVBI VaccinesN/A-C$0.97N/AN/AN/AN/AN/AN/AN/ALatest APM, DNA, VBV, and CUS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025DNAGinkgo Bioworks-$1.44N/AN/AN/AN/AN/A5/6/2025Q1 2025DNAGinkgo Bioworks-$1.23-$1.58-$0.35-$1.68$38.70 million$48.32 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAPMAptorum GroupN/AN/AN/AN/AN/ACUSChemtrade Electrochem Inc,C$0.022.44%N/AN/AN/ADNAGinkgo BioworksN/AN/AN/AN/AN/AVBVVBI VaccinesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAPMAptorum GroupN/A0.220.22CUSChemtrade Electrochem Inc,N/AN/AN/ADNAGinkgo BioworksN/A4.884.88VBVVBI Vaccines14.292.642.54Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAPMAptorum Group3.80%CUSChemtrade Electrochem Inc,N/ADNAGinkgo Bioworks78.63%VBVVBI VaccinesN/AInsider OwnershipCompanyInsider OwnershipAPMAptorum Group63.99%CUSChemtrade Electrochem Inc,N/ADNAGinkgo Bioworks9.72%VBVVBI VaccinesN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAPMAptorum Group305.35 million1.93 millionNot OptionableCUSChemtrade Electrochem Inc,60186.89 millionN/ANot OptionableDNAGinkgo Bioworks64058.53 million52.84 millionOptionableVBVVBI Vaccines2264.08 millionN/ANot OptionableAPM, DNA, VBV, and CUS HeadlinesRecent News About These CompaniesDecades of research push cytomegalovirus vaccine closer to realityJanuary 7, 2025 | msn.comFive Covid-19 vaccine false theories - debunkedOctober 26, 2024 | bbc.co.ukVBIVQ VBI Vaccines Inc.August 15, 2024 | seekingalpha.comVBI Vaccines Inc. (Nasdaq: VBIV) Rises from the Ashes and is NASDAQ Top Percentage GainerAugust 6, 2024 | investorideas.comIVBI Vaccines Starts Restructuring Procedure in CanadaJuly 30, 2024 | marketwatch.comVBI Vaccines secures court protection as it restructures, seeks buyer(s)July 30, 2024 | fiercebiotech.comFVBIV Stock Earnings: VBI Vaccines Beats EPS, Misses Revenue for Q4 2023April 16, 2024 | msn.comVBI Vaccines sells hepatitis B vaccine candidate, manufacturing digs to partner Brii Biosciences for up to $33 millionFebruary 14, 2024 | fiercepharma.comFThe Truth About VaccinesJanuary 6, 2024 | webmd.comWVBI Vaccines Inc VBIVOctober 31, 2023 | morningstar.comMAccess to new Covid-19 vaccines delayed for Vermonters on MedicaidSeptember 27, 2023 | vtdigger.orgVNo, Pfizer COVID-19 vaccine doesn't cause 'VAIDS.' That's not a real condition | Fact checkSeptember 26, 2023 | usatoday.comAvailability of new 2023–2024 COVID-19 vaccine in VirginiaSeptember 26, 2023 | newsleader.comNThe Consumer’s Guide to RSV Vaccines for Older AdultsSeptember 24, 2023 | everydayhealth.comEUpdated COVID-19 vaccine recommended for everyone; old, young, immunocompromised will benefit mostSeptember 23, 2023 | usatoday.comIs It Safe to Get Multiple Vaccines at the Same Time?September 22, 2023 | everydayhealth.comEThe real data behind the new COVID vaccines the White House is pushingSeptember 21, 2023 | nypost.comNNew COVID vaccines will be available in RI. Here's how to get one.September 20, 2023 | providencejournal.comPCOVID vaccine pill that kills virus before it infects the body could be comingSeptember 15, 2023 | nypost.comNInterim results show Brii’s therapeutic HBV vaccine induces immune responseSeptember 8, 2023 | bioworld.comBNew MarketBeat Followers Over TimeMedia Sentiment Over TimeAPM, DNA, VBV, and CUS Company DescriptionsAptorum Group NASDAQ:APM$1.97 +0.03 (+1.55%) Closing price 07/17/2025 04:00 PM EasternExtended Trading$1.86 -0.11 (-5.58%) As of 07/17/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Aptorum Group Limited, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic products for the treatment of infectious diseases and cancer. The company operates in the Therapeutics and Non-Therapeutics segments. Its pipeline products include SACT- 1 for neuroblastoma and other cancer types; SACT-COV19 for the treatment of coronavirus disease; ALS-4 to treat bacterial infections caused by staphylococcus aureus, including MRSA; and ALS-1 to treat viral infections caused by influenza virus A. The company is also developing ALS-2/3 for the treatment of gram+ve bacterial infections; RPIDD, a pathogen molecular diagnostic; NativusWell DOI (NLS-2), a dietary supplement; NLS-1 for the treatment of endometriosis; DLS-1+2 to treat NSCLC with mutation; DLS-3, an autoimmune small molecule; and CLS-1 for the treatment of obesity. Its pipeline products enable the discovery of new therapeutics assets, such as systematic screening of existing approved drug molecules, and microbiome-based research platforms for treatment of metabolic diseases. The company also focuses on therapeutic and diagnostic projects in neurology, gastroenterology, metabolic disorders, women's health, and other disease areas. In addition, it operates a medical clinic. The company was formerly known as APTUS Holdings Limited and changed its name to Aptorum Group Limited in October 2017. Aptorum Group Limited was incorporated in 2010 and is headquartered in London, the United Kingdom. Aptorum Group Limited is a subsidiary of Jurchen Investment Corporation.Chemtrade Electrochem Inc, TSE:CUSChemtrade Electrochem Inc, formerly Canexus Corp is a Canada-based company engaged in operating North American sodium chlorate production facilities; a North American chlor-alkali production facility and a sodium chlorate and chlor-alkali production facility. Its segments are North America Sodium Chlorate, North America Chlor-alkali (NACA) and South America (sodium chlorate and chlor-alkali). The North America Sodium Chlorate segment sells sodium chlorate to the South America segment and provides transloading services to the NACA segment for caustic soda transloaded from barges into trucks for delivery to NACA customers. It produces sodium chlorate in Beauharnois, Quebec; Brandon, Manitoba, and Nanaimo, British Columbia; chlor-alkali products (caustic soda, chlorine, and hydrochloric acid) in North Vancouver, British Columbia, and sodium chlorate and chlor-alkali products in Espirito Santo, Brazil. It caters its production to the pulp and paper, water treatment and oil and gas sectors.Ginkgo Bioworks NYSE:DNA$9.76 +0.16 (+1.64%) Closing price 07/17/2025 03:59 PM EasternExtended Trading$9.74 -0.02 (-0.17%) As of 07/17/2025 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.VBI Vaccines TSE:VBVVBI Vaccines Inc., a biopharmaceutical company, develops and sells vaccines to address unmet needs in infectious disease and immuno-oncology in Israel and internationally. The company offers Sci-B-Vac, a third-generation hepatitis B vaccine for adults, children, and newborns; and eVLP, a vaccine platform for the design of enveloped virus-like particle vaccines that closely mimic the target virus. It is also developing congenital cytomegalovirus vaccine candidate for infectious disease; and therapeutic glioblastoma multiforme vaccine candidate for immuno-oncology. The company was formerly known as SciVac Therapeutics Inc. and changed its name to VBI Vaccines Inc. in May 2016. The company is headquartered in Cambridge, Massachusetts. VBI Vaccines Inc. is a subsidiary of FDS Pharma ASS. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas High-Flying GE Aerospace Drops After Blowout Q2 — What Now? A New $70 Billion AI Investment Could Push Taiwan Semiconductor Why Prologis May Be the Smartest Backdoor Bet on AI Real Estate Is Amazon Really the Best Forever Stock for Your Portfolio? Qualcomm: Undervalued Chip Stock in Breakout Uptrend Broadcom’s Takes on NVIDIA: Why Tomahawk Ultra Could Boost Shares CrowdStrike Bulls Beware: This Trade May Be Getting Crowded AMD Just Triggered a Signal Traders Can’t Ignore Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
